Most people taking Wegovy at the full dose lose about 15% of their body weight over the first year to year and a half. For someone starting at 250 pounds, that works out to roughly 37 pounds. Results vary, but clinical trials consistently show this range, and some people lose significantly more.
What Clinical Trials Show
The largest Wegovy trials tracked thousands of adults over 68 to 104 weeks. In a 68-week study of 1,961 adults, 83% of people on the full 2.4 mg dose lost at least 5% of their body weight, compared with 31% on placebo. Nearly a third of participants in one trial lost 25% or more of their starting weight, while none in the placebo group hit that mark.
Over two full years, the results held up well. A 104-week study found that people on Wegovy lost an average of 15.2% of their body weight, compared with just 2.6% for those on placebo. That gap of about 12.6 percentage points represents the drug’s actual effect beyond what lifestyle changes alone would produce.
Results With Type 2 Diabetes
If you have type 2 diabetes, expect somewhat smaller losses. In a 68-week trial of adults with both obesity and type 2 diabetes, the average weight loss was 9.6%, compared with 3.4% on placebo. About 69% of participants lost at least 5% of their body weight. The difference likely comes down to how diabetes and related medications affect metabolism, but a 10% loss still delivers meaningful improvements in blood sugar control, blood pressure, and joint stress.
How Wegovy Works
Wegovy is a synthetic version of a gut hormone called GLP-1 that your body naturally releases after eating. The drug works on two fronts. First, it acts on appetite centers in the brain, dialing down hunger signals and making you feel satisfied with less food. Second, it slows how quickly your stomach empties, so meals keep you feeling full longer. The combination means most people simply want to eat less without the constant battle against cravings that derails traditional dieting.
The Dosing Ramp-Up Takes 4 Months
You don’t start on the full dose. Wegovy follows a gradual schedule designed to reduce side effects:
- Weeks 1 through 4: 0.25 mg once weekly
- Weeks 5 through 8: 0.5 mg
- Weeks 9 through 12: 1 mg
- Weeks 13 through 16: 1.7 mg
- Week 17 onward: 2.4 mg (the full maintenance dose)
This means noticeable weight loss usually starts picking up around months two and three, with the steepest losses happening once you reach the maintenance dose. If you can’t tolerate 2.4 mg, your prescriber may keep you at 1.7 mg, which still produces meaningful results.
Side Effects That Affect Staying on Track
The most common side effects are gastrointestinal: nausea, vomiting, and diarrhea. These tend to be worst during dose increases and usually improve over weeks as your body adjusts. About 4.3% of people in clinical trials stopped taking Wegovy because of gut-related side effects, with nausea being the top reason at 1.8%. That means the vast majority of people tolerate it well enough to continue, especially with the gradual dose escalation.
What Happens When You Stop
This is the part most people don’t hear about upfront. A large meta-analysis published in the BMJ found that people regain an average of about 10 kilograms (22 pounds) within the first year after stopping newer weight loss medications like Wegovy. The projected timeline for returning to baseline weight was roughly 1.5 years after discontinuation. In other words, without continued treatment or substantial lifestyle changes to compensate, most of the lost weight comes back. This is consistent with how obesity works as a chronic condition: the biological drivers of weight regain, including shifts in hunger hormones and metabolic rate, don’t resolve just because weight was lost.
This doesn’t mean stopping is always the wrong choice, but it’s worth understanding that Wegovy works best as a long-term treatment rather than a temporary fix.
Benefits Beyond the Scale
Weight loss in this range carries real health payoffs. The SELECT trial, which followed over 17,000 people with heart disease and obesity, found that Wegovy reduced the risk of major cardiovascular events like heart attacks and strokes by 20% compared with placebo. This was in people without diabetes, suggesting the cardiovascular benefits go beyond just blood sugar improvements. A 10 to 15% weight loss also reliably improves sleep apnea, knee and hip pain, blood pressure, and cholesterol levels.
What Realistic Expectations Look Like
Individual results spread across a wide range. Some people lose 25% or more of their body weight. Others plateau around 5 to 8%. Factors that influence your results include your starting weight, whether you have type 2 diabetes, how consistently you take the medication, and how much you change your eating and activity patterns alongside it. The clinical trial averages of 10 to 15% weight loss represent the middle of the bell curve, not a guarantee.
Most people see their weight loss begin to level off somewhere between 12 and 18 months. The two-year data suggest that once you reach that plateau, the weight stays off as long as you continue treatment. The first few months often feel slow because of the dose titration, so patience through the ramp-up period matters.